Gilead Sciences (NASDAQ: GILD), the world’s largest maker of HIV drugs, said it has formed a new cancer research collaboration with Yale University. Under the deal, Foster City, CA-based Gilead will provide $40 million to support research over the first four years, and has the option to extend the collaboration for 10 years, and a total of $100 million. Gilead will have the first shot at commercializing inventions that arise at Yale from the partnership. The research alliance is the latest move ahead for Gilead in cancer, coming on the heels of its acquisition of Seattle-based Calistoga Pharmaceuticals for as much as $600 million.
By posting a comment, you agree to our terms and conditions.